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exhibited various divergent mRNA abundances between 
L–E and H/W strains after TCDD treatment. Several genes 
displayed a biphasic response where the initial response to 
TCDD treatment was followed by a secondary response, 
usually of larger magnitude in L–E liver. This second-
ary response was most often an exaggeration of the origi-
nal TCDD-induced response. Only cytochrome b5 type A 
(microsomal) (Cyb5a) had equivalent TCDD sensitivity to 
the prototypic AHR-responsive cytochrome P450, family 
1, subfamily a, polypeptide 1 (Cyp1a1), while six genes 
were less sensitive. Four genes showed an early inter-strain 
difference that was sustained throughout most of the time 
course (atypical chemokine receptor 3 (Ackr3), collagen, 
type XVIII, alpha 1 (Col18a1), Cyb5a and glutamate dehy-
drogenase 1 (Glud1)), and of those genes examined in this 
study, are most likely to represent genes involved in the 
pathogenesis of TCDD-induced hepatotoxicity in L–E rats.
Keywords Aryl hydrocarbon receptor · 2,3,7,8 
Tetrachlorodibenzo-p-dioxin · TCDD · mRNA abundance · 
NanoString · Toxicity
Introduction
The environmental contaminant 2,3,7,8 tetrachlorodibenzo-
p-dioxin (TCDD) is a highly stable aromatic compound 
that causes a wide variety of toxic phenotypes. Specific 
toxic effects vary across species, but in mammals can 
include hepatic toxicity, chloracne, teratogenic effects, 
thymic atrophy, immune dysregulation, rapid weight loss 
(known as wasting syndrome) and cancer (Birnbaum and 
Tuomisto 2000; Pohjanvirta and Tuomisto 1994; White and 
Birnbaum 2009). TCDD is highly lipophilic and poorly 
metabolized, and thus bio-accumulates within fat stores 
Abstract 2,3,7,8 Tetrachlorodibenzo-p-dioxin (TCDD) 
is an aromatic, long-lived environmental contaminant. 
While the pathogenesis of TCDD-induced toxicity is 
poorly understood, it has been shown that the aryl hydro-
carbon receptor (AHR) is required. However, the specific 
transcriptomic changes that lead to toxic outcomes have 
not yet been identified. We previously identified a panel of 
33 genes that respond to TCDD treatment in two TCDD-
sensitive rodent species. To identify genes involved in the 
onset of hepatic toxicity, we explored 25 of these in-depth 
using liver from two rat strains: the TCDD-resistant Han/
Wistar (H/W) and the TCDD-sensitive Long–Evans (L–E). 
Time course and dose–response analyses of mRNA abun-
dance following TCDD insult indicate that eight genes 
are similarly regulated in livers of both strains of rat, sug-
gesting that they are not central to the severe L–E-spe-
cific TCDD-induced toxicities. The remaining 17 genes 
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of animals higher up the food chain and represents a long-
term, cumulative source of toxicity (Domingo and Bocio 
2007; Sinkkonen and Paasivirta 2000; van Birgelen and van 
den Berg 2000).
While TCDD exposure leads to toxicity in most verte-
brate species, there is a high degree of variation in suscep-
tibility, both between species and within species. Notably, 
the Han/Wistar (Kuopio) rat (H/W) is exceptionally resist-
ant to TCDD-induced toxicities (LD50 above 9600 μg/kg), 
while guinea pigs are at least 10,000-fold more sensitive, 
with an LD50 of 1–2 μg/kg (Pohjanvirta and Tuomisto 
1994; Pohjanvirta et al. 1999). Most mammalian species 
fall between these extremes: commonly used experimen-
tal models such as the Long–Evans (Turku/AB; L–E) rat 
and C57BL/6 mouse have intermediate sensitivity (LD50 
of 17.7 and ~182 μg/kg for male animals, respectively) 
(Pohjanvirta and Tuomisto 1994). In addition to variation 
in sensitivity among species, the specific tissues and organ 
systems affected by TCDD ingestion vary widely among 
species. In humans, the most obvious outcome of exposure 
to high doses of TCDD is chloracne, whereas wasting syn-
drome and delayed death are most notable in rodents (Sorg 
et al. 2009; Sweeney and Mocarelli 2000; Tuomisto et al. 
1995). Studies of human populations exposed to TCDD 
and related congeners (resulting from industrial accidents 
and food contamination) have implicated TCDD as a 
human carcinogen, although this finding is widely debated 
due to confounding factors (Consonni et al. 2008; Pesatori 
et al. 2009; Tuomisto and Tuomisto 2012; US-EPA 2003).
Despite wide variation in sensitivity and differing mani-
festations of toxicity among species, the toxic effects of 
TCDD have been mainly attributed to activation of the aryl 
hydrocarbon receptor (AHR) (Okey 2007). The AHR is a 
ligand-activated transcription factor of the Per-Arnt-Sim 
family and alters transcription of numerous genes (Kewley 
et al. 2004). Upon ligand binding, the AHR is translocated 
into the cell nucleus where it heterodimerizes with the aryl 
hydrocarbon nuclear translocator (ARNT), subsequently 
binding to AHR response elements (AHREs) in upstream 
regulatory regions of target genes such as Cyp1a1 (Linde-
bro et al. 1995). Studies in mice have shown that muta-
tions which reduce the affinity of AHR for TCDD cor-
relate with a reduction in toxic outcome (Birnbaum et al. 
1990; Okey et al. 1989). In the H/W rat, a point mutation 
that alters the AHR transactivation domain via alternative 
splicing imparts great resistance to TCDD-induced tox-
icities (Pohjanvirta et al. 1998; Simanainen et al. 2002). 
It is interesting that the resistance of H/W rats to the toxic 
effects of TCDD exposure occurs despite the variant H/W 
AHR maintaining the ability to regulate transcriptional 
changes in numerous “AHR-core” genes (such as Cyp1a1) 
in a manner similar to TCDD-sensitive L–E rats (Mof-
fat et al. 2010; Simanainen et al. 2002). Responses that 
are conserved between sensitive and resistant rat strains 
are termed type I, while responses that are enhanced in or 
exclusive to TCDD-sensitive L–E rats are termed type II 
responses (Simanainen et al. 2002, 2003).
It has also been shown that heterodimerization of the 
AHR with ARNT is required for TCDD-induced toxicity 
in mouse liver (Nukaya et al. 2010), and that mice hypo-
morphic for ARNT are resistant to TCDD-induced effects 
(Walisser et al. 2004a, b). However, the clearest evidence 
that TCDD toxicity is AHR dependent comes from stud-
ies of AHR knockout mice. Mice lacking an AHR do not 
suffer the toxic effects of TCDD (Bunger et al. 2003; Fer-
nandez-Salguero et al. 1996; Mimura et al. 1997; Vorder-
strasse et al. 2001). While some studies have identified 
non-genomic pathways leading to metabolic alterations (Li 
et al. 2010; Matsumura 2009), the studies discussed above 
indicate that DNA binding of the AHR:ARNT heterodimer 
is required to mediate the major toxic outcomes of dioxin 
exposure.
Identification of the key transcriptional changes that 
lead to toxicity in laboratory species has been difficult. 
Activation of the AHR alters the abundance of hundreds to 
thousands of different mRNAs (Boutros et al. 2008; Bover-
hof et al. 2006; Forgacs et al. 2013; Sato et al. 2008; Tijet 
et al. 2006). While a core set of genes is affected across 
a wide biological spectrum (termed “AHR-core” genes), 
the majority of transcriptomic responses appear to depend 
upon the species, strain, tissue and cell type (Boutros et al. 
2008; Boverhof et al. 2006; Carlson et al. 2009; Puga et al. 
2004; Watson et al. 2013). In general, “AHR-core” genes 
are involved in pathways for detoxification (e.g. Cyp1a1), 
oxidative stress [e.g. nuclear factor, erythroid 2-like 2 
(Nfe2l2)] and negative feedback regulation [e.g. aryl hydro-
carbon receptor repressor (Ahrr)]. This complex variation 
in transcriptional response is coupled to a large degree of 
intra-species and even intra-strain variation in the pattern of 
phenotypic responses to TCDD treatment described above. 
Indeed, the large intra-species variability in TCDD-induced 
changes is a reflection of large differences in the basal tran-
scriptome across strains of rats (Yao et al. 2012) and mice 
(Pritchard et al. 2006).
Fortunately, these variations also provide a tool that 
can be used to identify genes involved in toxicity. Recent 
studies by our group (Boutros et al. 2008) and oth-
ers (Boverhof et al. 2006) have compared mouse and rat, 
two TCDD-sensitive laboratory animals that have similar 
phenotypic responses to TCDD. Comparison of hepatic 
mRNA abundance changes following TCDD treatment 
identified several genes which were dysregulated in both 
species and may be involved in the onset of liver toxicity. 
While each of these studies identified 33 genes that were 
similarly regulated in both mouse and rat, only three genes 
[Cyp1a1, NAD(P)H dehydrogenase, quinone 1 (Nqo1) and 
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glutamate dehydrogenase 1 (Glud1)] were identified in 
both studies. Continuing from the detailed analysis of eight 
“AHR-core” genes (Watson et al. 2013), the remaining 25 
TCDD-responsive genes identified in our rat–mouse com-
parison are analysed in detail here. We compare changes 
in hepatic mRNA abundance between the TCDD-resistant 
H/W rat and the TCDD-sensitive L–E rat. By identifying 
genes whose expression differs between dioxin-sensitive 
and dioxin-resistant rats following TCDD exposure, we 
have identified candidate regulators of type II phenotypic 
responses.
Methods and materials
Animal handling
Samples used in this study were the same as previously 
described (Watson et al. 2013). This manuscript does not 
contain any clinical studies or patient data. Study plans 
were approved by the Kuopio Provincial Government and 
the Animal Experiment Committee of the University of 
Kuopio. Briefly, four experimental (TCDD treated) rats 
were used for each dose studied (0.001, 0.01, 0.1, 1, 10, 
50, 100, 1000 or 3000 μg/kg, Fig. S1), and livers were har-
vested 19-h post-gavage with TCDD in corn oil. The time 
course study animals were treated with a single 100 μg/kg 
dose of TCDD in corn oil, and the liver was harvested at the 
appropriate times following treatment; L–E animals were 
harvested at 3-, 6-, 10-, 19-, 96- and 240-h post-TCDD 
treatment (n = 4, 4, 4, 4, 4, 5, respectively), and H/W ani-
mals were harvested at 1.5, 3, 6, 10, 19, 96, 240 and 384 h 
after TCDD treatment (n = 3, 4, 4, 4, 4, 5, 5, 4, respec-
tively). In addition, animals treated by gavage with corn oil 
vehicle were harvested at several time points as controls 
[L–E: 19, 96 and 240 h (n = 7, 4, 5, respectively), H/W: 
1.5, 19, 96, 240 and 384 h (n = 3, 7, 5, 5, 4, respectively), 
Fig. S1]. Animal weights are reported in File S1. ARRIVE 
guidelines for reporting animal experimentation were fol-
lowed (Kilkenny et al. 2010) as outlined in the ARRIVE 
checklist (File S2).
RNA isolation
RNA was extracted from rat liver using RNeasy Mini kits 
(Qiagen, Mississauga, Canada) following the manufactur-
er’s recommended protocol. RNA was quantified using a 
NanoDrop spectrophotometer, and the integrity of the RNA 
was verified by electrophoresis on an Agilent 2100 Bioana-
lyzer, using RNA Nano 6000 total RNA assays. Only RNA 
samples with an RNA integrity number (RIN) greater than 
8.5 were used in downstream analyses. RIN numbers are 
available in Watson et al. (2013), as Supplementary File 1.
RNA analysis
RNA was diluted to a concentration of 50 ng/µl, and 50 µl 
of each sample was loaded into one well of a 96-well plate 
and sent to the UHN Microarray Centre (Toronto, ON) on 
dry ice for analysis on a NanoString nCounter. Desired 
mRNA targets were submitted in advance, and probes were 
designed and synthesized by NanoString prior to RNA 
analysis. Probes were verified by BLAST analysis (John-
son et al. 2008), searching the Rattus norvegicus nr/nt 
database to ensure that each identified a single gene. The 
CodeSet (the multiplexed collection of 54 distinct probes) 
used is provided in File S2. All raw and pre-processed data 
and the CodeSet have been deposited in the NCBI’s Gene 
Expression Omnibus (Edgar et al. 2002) as GSE43251. 
Each sample was analysed in a separate hybridization reac-
tion containing the entire CodeSet, and the NanoString 
data were pre-processed as previously described (Watson 
et al. 2013). The NanoStringNorm (version 0.9.4) package, 
designed for use in the R statistical environment, provides 
all pre-processing methods for NanoString data (Waggott 
et al. 2011). Since time-matched vehicle controls were not 
available for all time points, the 19-h vehicle control was 
used as the basal level for subsequent analyses. Statistical 
analysis indicated that use of the 19-h control instead of the 
available time-matched controls did not significantly alter 
the results (Supplementary Fig. 3 of Watson et al. 2013).
Statistical analysis
Data were analysed in the R statistical environment (version 
3.2.1) using unpaired Student’s t tests to compare strains, 
doses and time points (Ihaka and Gentleman 1996). p val-
ues were false discovery rate corrected (padjusted) to adjust 
for multiple testing (Storey and Tibshirani 2003). ED50 
values with 90 % confidence intervals were determined by 
fitting response curves using a four-parameter log-logistic 
model ( f (x) = c+ [{d − c}/1+ exp(b(log(x)− e˜))]), 
where b = slope at the inflection point, c = lower limit, 
d = upper limit and e˜ = log(ED50)) using the R package 
drc (version 2.5-12). ED50 with 90 % confidence intervals 
was determined by drc as part of the curve fitting. Differ-
ences in ED50 parameter values were determined between 
strains and p values generated by means of approximate t 
tests (Ritz and Streibig 2005). Data were visualized using 
the lattice (version 0.20-33) and latticeExtra (version 0.6-
26) packages via the BPG package (P’ng et al. submitted; 
version 5.3.4). All error bars represent standard error of the 
mean. ED50 values were compared using inferential confi-
dence intervals with Δ = 2 × ED50 90 % confidence range 
for Cyp1a1 to determine whether any gene(s) had an ED50 
value statistically equivalent to Cyp1a1 (Beckstead 2008; 
Tryon and Lewis 2008).
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Results
We previously identified 33 genes that may be involved in 
the onset of TCDD toxicity, having changes in liver mRNA 
abundance that occur in common between two rodent spe-
cies that display similar phenotypic responses to TCDD 
(Boutros et al. 2008). The goal of our current study was 
to validate and prioritize candidate genes for subsequent 
mechanistic analysis. We chose to examine the less-stud-
ied TCDD-responsive genes by excluding the well-docu-
mented “AHR-core” genes. Here, we compare changes in 
hepatic mRNA abundances following TCDD treatment of 
TCDD-sensitive L–E rats with TCDD-resistant H/W rats. 
These rat strains differ widely in their phenotypic response 
to TCDD (Pohjanvirta et al. 1999). We therefore hypoth-
esize that genes displaying conserved responses in TCDD-
sensitive L–E rats and C57BL/6 mice but that demonstrate 
differential expression patterns between L–E and TCDD-
resistant H/W rats play a role in the onset of toxicity.
Time course analysis
The NanoString platform was used to analyse effects of 
TCDD treatment on the mRNA abundance of a subset 
of TCDD-regulated genes in livers of H/W and L/E rats. 
The utility of the approach has been validated previously 
by analysis of a well-characterized TCDD-regulated gene, 
Cyp1a1 (Watson et al. 2013). A summary of the mRNA 
abundance changes for all genes examined is shown in 
Fig. 1. Eight genes showed similar mRNA responses fol-
lowing TCDD treatment in both strains (growth factor, 
augmenter of liver regeneration (Gfer), influenza virus 
NS1A-binding protein (Ivns1abp), phenazine biosynthesis-
like protein domain containing 1 (Pbld), phosphodiesterase 
2A (Pde2a), proteasome maturation protein (Pomp), sol-
ute carrier organic anion transporter family, member 1a1 
(Slco1a1), tropomyosin 1, alpha (Tpm1) and UV radiation 
resistance-associated gene (Uvrag); Figs. S2–S9). Differ-
ences in the mRNA response profiles for L–E and H/W 
rats were defined as those with significantly different inter-
strain mRNA abundances (in the same direction) at two or 
more consecutive time points (padjusted < 0.10). This crite-
rion was met for 17/25 genes (Ackr3, cysteine conjugate-
beta lyase, cytoplasmic (Ccbl1), Col18a1, Cyb5a, derlin 1 
(Derl1), echinoderm microtubule-associated protein like 
4 (Eml4), endoplasmic reticulum to nucleus signalling 1 
(Ern1), exocyst complex component 3 (Exoc3), growth 
hormone receptor (Ghr), Glud1, LIM and SH3 protein 1 
(Lasp1), neuraminidase 1 (Neu1), TP53 apoptosis effector 
(Perp), phosphomannomutase 1 (Pmm1), proteasome subu-
nit beta 4 (Psmb4), syndecan 1 (Sdc1) and sulfiredoxin 1 
(Srxn1); Fig. 2, Figs. S10–S22). Furthermore, we deemed 
it most likely that a gene responsible for prolonged tox-
icity would exhibit significant inter-strain differences at 
three or more consecutive time points. Using these criteria, 
four genes were identified as being potentially involved in 
L–E-specific hepatic toxicity (Ackr3, Cyb5a, Col18a1 and 
Glud1, Fig. 3). While Ghr did not meet the above criteria 
for inter-strain differences, it demonstrated significantly 
different inter-strain mRNA abundance at four of the six 
time points (Fig. S15).  
Genes could also be subdivided into groups defined 
by the time at which mRNA abundance began to devi-
ate between H/W and L–E. Nine genes were observed to 
have differential inter-strain mRNA abundances beginning 
earlier than 10 h post-treatment (Ackr3, Ccbl1, Col18a1, 
Exoc3, Ghr, Glud1, Lasp1, Psmb4 and Sdc1; Fig. 2 and 
Figs. S10, S14–S16, S20, S21), while eight genes deviated 
at 10 h or later after TCDD exposure (Cyb5a, Derl1, Eml4, 
Ern1, Neu1, Perp, Pmm1 and Srxn1; Fig. 3 and Figs. S11–
S13, S17–S19, S22).
“Biphasic” responses
Nine genes demonstrated “biphasic” mRNA abundance 
changes in response to the 100 µg/kg TCDD treatment. 
These genes reached an initial plateau or peak early after 
treatment (between 3- and 10-h post-treatment) followed 
by a secondary response, which in most cases represented 
an extension or exaggeration of the original change. The 
exception to this trend was Ern1, where an initial repres-
sion caused by TCDD treatment was reversed beginning 
at 19-h post-treatment in L–E rat liver. The abundance of 
Ern1 rapidly returned to near control levels in L–E animals, 
but remained reduced in H/W liver (Fig. S13). In all other 
instances (Ackr3, Ccbl1, Exoc3, Neu1, Pde2a, Perp, Pmm1 
and Sxrn1; Fig. 3; Figs. S5, S10, S14 S17–S19 and S22), 
L–E animals displayed a secondary exaggeration of the ini-
tial TCDD-induced change. H/W animals often exhibited 
the biphasic mRNA abundance pattern; however, with the 
Fig. 1  Summary of transcriptional responses to TCDD exposure. 
Summary of mRNA abundance changes of all examined genes fol-
lowing TCDD treatment with animals evaluated along either a time 
course (a) or dose–response (b) experiment. Dot size Magnitude of 
change as a per cent of the maximal normalized expression level for 
that gene in either H/W or L–E rat (whichever strain has the high-
est expression level) to allow for direct comparison between strains. 
Shading of individual squares represents the FDR-adjusted p value 
for an unpaired Student’s t test comparing TCDD-induced expression 
to the 19-h vehicle control for each strain. Differences from vehicle 
controls were considered significant if two consecutive points in the 
time course (normalized expression levels, not fold change) were sta-
tistically significant at a padjusted < 0.10, resulting in an FDR-adjusted 
joint probability of <0.01. H/W values are represented by blue circles, 
while L–E are represented by orange circles (colour figure online)
▸
329Arch Toxicol (2017) 91:325–338 
1 3
330 Arch Toxicol (2017) 91:325–338
1 3
exception of Ern1, the L–E secondary response occurred to 
a much larger magnitude than that observed in H/W liver.
Dose–response analysis
Dose–response analyses were performed for all genes of 
interest at 19-h post-TCDD treatment. In most instances, 
the log dose–response curves presented the expected clas-
sic sigmoidal shape (Fig. S23). For some genes, both 
the dose–response and time course exhibited a muted 
response, indicating that the gene was poorly or non-
responsive to TCDD at 19 h (Uvrag; Fig. 1; Figs. S9, S23). 
In general, the dose–response profiles showed less inter-
strain variation than the time course analyses. For instance, 
Ccbl1 displayed significant inter-strain differences in 
mRNA abundance at 3-, 6- and 240-h post-treatment; how-
ever, no difference was detected at the 19-h time point used 
for the dose–response study (Fig. S10). In contrast, Cyb5a 
is near its maximal time course response in H/W rats at 
19 h and this was reflected by the changes observed using 
the dose–response approach (Fig. 3, Fig. S23). Only two 
genes had significant inter-strain differences in their ED50 
values (Cyb5a and Psmb4; Table 1; Fig. S23). However, 
Ackr3 could also be included here as it showed a very clear 
difference in the dose–response; L–E rats had an ED50 of 
8.3 µg/kg, whereas the ED50 for H/W was not determina-
ble since this gene was unresponsive in this strain until 
240-h post-exposure (Fig. 3). Three additional genes had 
an ED50 determined for only one strain (Lasp1, Srxn1 and 
Tpm1). Lasp1 and Srxn1 were determined to have an ED50 
of 4.06 and 0.60 µg/kg, respectively, in L–E animals while 
Tpm1 had an ED50 of 0.30 in H/W rats (Table 1 and Fig. 
S23).
Fig. 2  Summary of mRNA abundance changes following TCDD 
treatment. The dot size represents H/W per cent change—L–E per 
cent change values. Shading of individual squares represents the 
FDR-adjusted p value for an unpaired Student’s t test comparing the 
inter-strain differences. Orange circles indicate higher abundance in 
L–E, while blue circles indicate higher abundance in H/W. A red box 
to the right of the gene symbol indicates that this gene had a statisti-
cally significant difference between strains at two or more consecu-
tive time points (colour figure online)
Fig. 3  Ackr3, Cyb5a, Col18a1 and Glud1 are genes with prolonged 
differential responses. Hepatic mRNA abundances of Ackr3, Cyb5a, 
Col18a1 and Glud1 display significantly differences in response 
between strains at three or more consecutive time points following 
TCDD treatment. a Normalized mRNA abundance time course pro-
files of TCDD-treated animals; b animals were similarly evaluated 
along a dose–response study with samples collected at 19-h post-
treatment. Asterisk indicates padjusted < 0.1 when comparing H/W to 
L–E using an unpaired Student’s t test
▸
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Sensitivity to TCDD
Of the 25 genes we examined, only Cyb5a (L–E, ED50 
0.01) demonstrated TCDD sensitivity equivalent to the 
prototypic AHR-regulated gene, Cyp1a1 [ED50 0.013 
(H/W), 0.035 (L–E), (Watson et al. 2013)], while six genes 
displayed lower sensitivity. These genes [Ackr3, Ccbl1 
(L–E), Cyb5a (H/W), Derl1 (L–E), Eml4 (L–E) and Exoc3; 
Table 1, Fig. 23] had an ED50 significantly higher than that 
of Cyp1a1. Of these, Ackr3 was the only gene with an ED50 
similar to the LD50 of male L–E rats (8.62 vs. 17.7 µg/kg, 
respectively), while having an undetermined ED50 in H/W.
Discussion
Previously, we identified 30 genes that exhibited concord-
ant hepatic mRNA responses between two TCDD-sensitive 
rodent species following TCDD treatment, along with three 
genes that demonstrated divergent responses (Boutros et al. 
2008). These 33 genes are candidate mediators of TCDD-
induced hepatotoxicity in TCDD-sensitive rodents. Liver 
was selected for study because numerous studies show 
extensive biochemical and pathologic changes in liver fol-
lowing dioxin exposure (Forgacs et al. 2012; Pohjanvirta 
et al. 1989, 1990; Viluksela et al. 2000, 1999). Further, 
Table 1  Genes analysed for differential responses
The column labelled “Absolute Difference” denotes the maximal absolute difference in mRNA counts (time course) between L–E and H/W rats. 
The “Difference as Percent” column is the “Absolute Difference” value as a per cent of the maximal TCDD-induced change for that gene. *Indi-
cates a difference with padjusted value <0.1 for between strain ED50 values
a ED50 value significantly different from the prototypical AHR-regulated gene, Cyp1a1 (Watson et al. 2013)
b Significant equivalence to Cyp1a1
c Pomp shows two consecutive points that are significantly different between strains; however, the differences are not consistent—one time point 
has significantly reduced abundance, whereas the other shows significant induction. ND indicates that the ED50 could not be determined for that 
gene
Gene symbol TCDD response Strain-related 
difference
ED50 H/W µg/kg ED50 L–E µg/kg Difference as per 
cent
Absolute difference Gene ID
Ackr3 Induced Higher in L–E ND 8.30a 96.0 3984 84,348
Ccbl1 Induced Transiently lower 
in L–E
3.93a 4.13a 28.3 460 311,844
Col18a1 Repressed Lower in L–E ND ND 51.6 1204 85,251
Cyb5a Induced (H/W) Higher in H/W 0.10a 0.01b* 59.8 25,321 64,001
Derl1 Induced Higher in L–E 7.43 1.06a 19.6 260 362,912
Eml4 Induced Higher in L–E 0.32 0.94a 36.3 539 313,861
Ern1 Repressed Higher in L–E 3.47 0.05 48.9 136 498,013
Exoc3 Induced Higher in L–E 2.28a 4.42a 35.3 780 252,881
Gfer None None ND 0.62 15.0 74 27,100
Ghr Repressed Lower in L–E 0.62 0.31 56.4 2303 25,235
Glud1 Repressed Lower in L–E 3.07 1.22 36.7 1291 24,399
Ivns1abp Repressed None 1.65 1.55 16.4 192 289,089
Lasp1 Repressed Variable ND 4.06 30.0 195 29,278
Neu1 Induced Higher in L–E 0.56 2.74 56.9 499 24,591
Pbld Induced None 0.47 0.56 12.3 2143 171,564
Pde2a Induced None 0.33 0.41 40.7 371 81,743
Perp Induced Higher in L–E 1.49 1.04 28.4 904 292,949
Pmm1 Induced Higher in L–E 1.76 1.01 66.4 372 300,089
Pomp None Nonec ND ND 20.5 851 288,455
Psmb4 Repressed Transiently lower 
in L–E
1.07 0.10* 22.9 394 58,854
Sdc1 Repressed Transiently lower 
in L–E
0.46 0.27 38.7 513 25,216
Slco1a1 Repressed None 5.84 0.05 35.6 261 50,572
Srxn1 Induced Higher in L–E ND 0.60 61.7 252 296,271
Tpm1 Induced None 0.30 ND 38.0 26 24,851
Uvrag None None ND ND 24.1 117 308,846
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unlike other potential target organs such as white adipose 
tissue or hypothalamus where few mRNAs are altered 
by TCDD exposure (Houlahan et al. 2015a, b), hundreds 
to thousands of rat liver genes are modulated by the acti-
vated AHR following TCDD exposure (Boutros et al. 2011; 
Boverhof et al. 2006; Fletcher et al. 2005; Franc et al. 
2008; Vezina et al. 2004; Yao et al. 2012). Our goal was 
to prioritize the 25 non-“AHR-core” genes of this cohort 
for further mechanistic investigation. Rat strains with strik-
ing differences in susceptibility to TCDD toxicities were 
selected: H/W rats are essentially unaffected by doses that 
are lethal to L–E rats (Tuomisto et al. 1999). Inter-strain 
differences in the abundance profiles for a specific mRNA 
that occur before or at the onset of toxicity may indicate 
genes mechanistically involved in TCDD-induced type II 
toxicity. Further, genes involved in L–E-specific toxicity 
might be expected to be more sensitive to TCDD treatment, 
having a lower ED50 for these genes in L–E than in H/W 
animals, or the genes may only be responsive in L–E. It 
has been shown that the earliest manifestations of toxicity 
occur rapidly, with TCDD-induced weight loss and changes 
in blood chemistry measurable within 24 h (Linden et al. 
2014). Interestingly, the onset of biochemical or physio-
logical changes in response to TCDD occurs at a time very 
close to that observed for the “biphasic” changes in mRNA 
abundance suggested for Ackr3, Ccbl1, Ern1, Exoc3, Neu1, 
Pde2a, Perp, Pmm1 and Sxrn1.
Of the 25 genes examined, eight are unlikely to be 
directly involved in type II toxic responses to TCDD, since 
they exhibited similar responses to TCDD in both TCDD-
sensitive and TCDD-resistant strains throughout the time 
course study and at all doses tested (Gfer, Ivns1abp, Pbld, 
Pde2a, Pomp, Slco1a1, Tpm1 and Uvrag Fig. S2–S9). The 
remaining 17 displayed some degree of inter-strain differ-
ential mRNA abundance following TCDD exposure. Most 
of these demonstrated enhanced or exaggerated effects in 
response to TCDD exposure in TCDD-sensitive L–E rats. 
Only Cyb5a (one of the four genes that displayed a sig-
nificant, prolonged inter-strain difference) had an enhanced 
response in the TCDD-resistant H/W liver, with an ~two-
fold up-regulation beginning early (6 to 10 h) after expo-
sure, as compared to essentially no change in L–E liver 
(Fig. 3). This H/W-specific gene modulation had previously 
been observed for Cyb5a and other six genes (Boutros et al. 
2011). It is possible that Cyb5a and other H/W-specific 
gene responses to TCDD play a protective role, amelio-
rating toxic outcomes. Comparison of the genomic DNA 
sequences for H/W and L–E rat did not identify any differ-
ences in AHREs within 3 kilobases of the transcriptional 
start site for any of the genes (Boutros, PC and Prokopec 
SD, in preparation). Of note, Cyb5a has recently been 
shown to be involved in the kynurenine pathway, its gene 
product acting as the major reducing agent of indoleamine 
2,3-dioxygenase (IDO), the first and rate-limiting step 
(Maghzal et al. 2008). Altered tryptophan metabolism fol-
lowing TCDD treatment with increased circulating lev-
els of tryptophan in TCDD-sensitive rat strains including 
L–E and concomitant decreases in tryptophan dioxygenase 
activity in rat liver has been observed (Unkila et al. 1994, 
1995, 1998, 1999; Weber et al. 1994). Further, Cyb5a has 
been shown to play a role in promoting autophagy in pan-
creatic cancer cells (Giovannetti et al. 2014). Promotion of 
autophagy has also been shown to reduce steatohepatitis 
and fibrosis in mouse liver (Lodder et al. 2015; Zhong et al. 
2015), perhaps representing a mechanism by which Cyb5a 
protects H/W rats.
Following TCDD treatment, liver Ghr (growth hormone 
receptor) is lower at four time points, separated by a single 
non-significant difference at 19 h in TCDD-sensitive L–E 
when compared to that observed in TCDD-resistant H/W 
(Fig. S15). This gene could be involved in both early and 
late responses to TCDD exposure. AHR activation leads 
to suppression of Ghr mRNA levels in livers of TCDD-
sensitive mice (Nukaya et al. 2004). Reduced Ghr mRNA 
abundance in TCDD-sensitive L–E rats may play a signifi-
cant role in the pathogenesis of many well-known TCDD-
induced toxic outcomes. Following a lethal dose of TCDD, 
L–E rat liver undergoes accumulation of fat and infiltration 
of inflammatory cells (steatohepatitis), while this does not 
occur in H/W rats given the same dose of TCDD (Pohjan-
virta et al. 1989, 1990). Similarly, reduction in growth hor-
mone signalling by liver-specific knockout of Stat5 leads 
to steatohepatitis, glucose intolerance, late onset obesity, 
impaired liver regeneration and insulin resistance (Baik 
et al. 2011). Liver-specific knockout of Ghr in mice reca-
pitulated the Stat5 knockout phenotype and also led to non-
alcoholic fatty liver disease, fibrosis and hepatocellular car-
cinoma (Fan et al. 2014). Signalling through the GHR also 
directly affects metabolism and insulin secretion (Strobl 
and Thomas 1994), as well as sex steroid metabolism (Baik 
et al. 2011), immune function and apoptosis (Savino et al. 
2002).
The remaining three genes with prolonged inter-strain 
differences produce proteins involved in metabolic pro-
cesses, angiogenesis, cytokine response, liver survival, 
liver repair and regeneration. The first of these, Glud1 
(glutamate dehydrogenase 1), is a mitochondrial enzyme 
that catalyses the reversible conversion of glutamate to 
α-ketoglutarate and regulates several important meta-
bolic and neurological pathways. The mRNA abundance 
of Glud1 is reduced in both strains but to a greater extent 
in TCDD-sensitive L–E rats. Glutamate plays a key role 
in regulation of energy homoeostasis in an organ-specific 
manner (reviewed by Karaca et al. 2011). In pancreatic islet 
cells for instance, decreased Glud1 activity reduced insu-
lin release, leading to organism-wide metabolic alterations. 
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Reduced plasma insulin levels following TCDD treatment 
in Sprague–Dawley rats have been observed (Gorski et al. 
1988; Gorski and Rozman 1987).
Col18a1 mRNA abundance was significantly lower 
in L–E rat at early (3–10 h, Fig. S3) and late time points 
following TCDD insult. It will be interesting to determine 
whether the decreased mRNA abundance is correlated 
with decreased amounts of both mature COL18A1 and/
or decreased amounts of active peptide domains. These 
early differences between L–E and H/W may indicate that 
Col18a1 is involved in the early stages of TCDD hepato-
toxicity, while the late difference may indicate it also is 
involved in TCDD-induced cancer or other delayed toxici-
ties (Viluksela et al. 2000). COL18A1 mutations that lead 
to deficiency in its cleavage product, endostatin, have been 
shown to lead to cancer (Mahajan et al. 2010). Interest-
ingly, COL18A1 contains amino terminal domains which, 
upon proteolytic cleavage, inhibit blood vessel formation 
(Zhuo et al. 2011), reduce cellular proliferation (Zhang 
et al. 2012) and block WNT signalling (Lavergne et al. 
2011; Quelard et al. 2008; Seppinen and Pihlajaniemi 
2011). Importantly, COL18A1 is an essential survival fac-
tor following acute liver toxicity from CCl4 (Duncan et al. 
2013).
Ackr3 displays the largest and most prolonged change 
that we observed in L–E rat (Fig. 3, all time points and 
maximally >16-fold difference from H/W rat). Interest-
ingly, the ED50 for Ackr3 in L–E rats is ~8.3, while the 
there was no change observed in H/W rat for any doses 
tested at 19 h. Since Ackr3 responds only in the sensitive 
L–E strain, has an early response and exhibits an ED50, 
similar to the LD50 for TCDD in L–E rats (male ~17.7 µg/
kg), it closely resembles the expected profile for genes 
causative of TCDD toxicity. It has been shown that the 
ED50 values for toxic outcomes following TCDD exposure, 
such as thymic atrophy and wasting syndrome, are simi-
lar to the LD50 values in Sprague–Dawley rats (Hanberg 
et al. 1989). Ackr3 binds to cytokines SDF-1 and ITAC, 
and has been implicated in cellular migration and invasion 
(Naumann et al. 2010; Tarnowski et al. 2010). Ackr3 has 
also been implicated in hypoxia response, tumour develop-
ment, cell growth, cell survival and adhesion (Burns et al. 
2006; Hu et al. 2010; Liu et al. 2010; Staton et al. 2011; 
Sun et al. 2010). Further, it plays a role in the brain and 
may be involved in modulation of anxiety and other behav-
iour (Guyon 2014; Ikeda et al. 2013). Recently, Ackr3 has 
been identified as a liver injury-inducible liver sinusoidal 
endothelial cell (LSEC)-specific SDF-1 receptor (Ding 
et al. 2014). Induction of Ackr3 in LSECs stimulates liver 
regeneration and reduces fibrosis. This is unexpected since 
other reports have shown that TCDD exposure increases 
expression of molecular markers of fibrosis in mice (Pierre 
et al. 2014). Activated Ackr3 has been shown to increase 
uptake of VLDL and cholesterol into adipose tissue, reduc-
ing circulating levels (Li et al. 2014). It is expressed at very 
low levels in normal hepatic tissue, but is highly expressed 
in murine hepatocellular carcinoma, predominantly in 
epithelial cells (Monnier et al. 2011). Ackr3 inhibition or 
inactivation reduces head and neck tumour growth and 
increases survival of mice with brain cancer (Maussang 
et al. 2013; Walters et al. 2014).
Of the 33 genes identified in our previous compari-
son of two TCDD-sensitive rodent species, mice and 
rats, we analysed here the 25 non-“AHR-core” genes 
in-depth to further characterize candidate mediators 
of TCDD toxicity. Of these, four genes displayed an 
inter-strain difference that persisted for 240 h or more 
(Ackr3, Cyb5a, Col18a1 and Glud1) with significantly 
different mRNA responses in livers of TCDD-resistant 
H/W versus TCDD-sensitive L–E rats. Since L–E rats 
are susceptible to TCDD-induced toxicities, whereas 
H/W rats are essentially refractory to them; these genes 
may play essential roles in the onset of toxicity. This 
study takes a key step towards identification of the 
specific genes and metabolic pathways which under-
lie toxic outcomes induced by TCDD by showing that 
eight TCDD-altered genes are unlikely to be involved 
in TCDD toxicity (Gfer, Ivns1abp, Pbld, Pde2a, Pomp, 
Slco1a1, Tpm1 and Uvrag), while identifying four 
genes (Ackr3, Cyb5a, Col18a1 and Glud1) that could 
play a key role in toxic outcomes. Future studies will 
be required to determine whether the reported changes 
in mRNA abundance lead to downstream changes in 
protein abundance, enzyme activities or sub-cellular 
location.
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